Try our Advanced Search for more refined results
February 28, 2017
Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company
Case Number:
17-1694
Court:
Nature of Suit:
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
February 07, 2019
Fed. Circ. Kills Patent Fight After Momenta Ditches Biosimilar
Momenta Pharmaceuticals Inc. can't challenge a patent for Bristol-Myers Squibb Co.'s rheumatoid arthritis drug Orencia because Momenta has stopped developing a biosimilar version of the blockbuster product, the Federal Circuit ruled Thursday.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login